Engineered immune cells take on tough lupus cases
NCT ID NCT06222853
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This early-stage study tests whether a special type of immune cell, called CAR-T, can safely treat people with severe lupus that hasn't improved with standard treatments. The therapy targets a protein called CD19 on immune cells to calm the overactive immune system. The main goal is to check for side effects, with a secondary look at whether it reduces lupus disease activity. The study involves 22 participants aged 5 and older.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310052, China
Conditions
Explore the condition pages connected to this study.